Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Intravesical oncolytic viral therapy using attenuated, replication‐competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model
Ist Teil von
The FASEB journal, 2001-05, Vol.15 (7), p.1306-1308
Ort / Verlag
United States: Federation of American Societies for Experimental Biology
Erscheinungsjahr
2001
Link zum Volltext
Quelle
Wiley Blackwell Single Titles
Beschreibungen/Notizen
ABSTRACT
Attenuated, replication‐competent herpes simplex virus mutants are attracting interest because of their ability to replicate within and kill tumor cells while remaining of low pathogenicity to normal tissues. In this study we investigated the ability of two oncolytic candidates, G207 and NV1020, to infect and lyse human and murine transitional cell carcinoma (MBT‐2) cells in vitro and their in vivo efficacy in a well‐established immunocompetent animal model of bladder cancer. Both viruses were effective at infecting, replicating within, and achieving subsequent cell lysis for all four human bladder cancer cell lines and MBT‐2. We found a strong correlation between infection efficiency and subsequent cell death. In vivo studies demonstrated that these viruses were effective with a single intravesical instillation and even more effective with multiple instillations at reducing tumor burden and achieving cures of orthotopic bladder cancer in syngeneic C3h/Hej mice. Immunohistochemistry and histological studies demonstrated that viral replication and cell death were restricted to bladder cancer cells. These results suggest that both G207 and NV1020 hold particular promise for intravesical treatment of human bladder cancer and that ease of intravesical instillation facilitates efficient delivery of virus to tumor cells.